<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance use and addiction treatment</journal-title></journal-title-group><issn pub-type="ppub">2949-8767</issn><issn pub-type="epub">2949-8759</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10947919</article-id><article-id pub-id-type="pmcid-ver">PMC10947919.319</article-id><article-id pub-id-type="pmcaid">10947919</article-id><article-id pub-id-type="pmcaiid">10947919</article-id><article-id pub-id-type="manuscript-id">NIHMS1954143</article-id><article-id pub-id-type="pmid">38122988</article-id><article-id pub-id-type="doi">10.1016/j.josat.2023.209281</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1954143</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1954143</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>McCann</surname><given-names initials="NC">Nicole C.</given-names></name><degrees>BA</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>LaRochelle</surname><given-names initials="MR">Marc R.</given-names></name><degrees>MD, MPH</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morgan</surname><given-names initials="JR">Jake R.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Health Law, Policy, and Management, Boston University School of Public Health</aff><aff id="A2"><label>2</label>Grayken Center for Addiction, Boston Medical Center</aff><aff id="A3"><label>3</label>Department of Medicine, Boston University School of Medicine</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author statement</p><p id="P2"><bold>McCann:</bold> conceptualization, formal analysis, methodology, writing-original draft; <bold>LaRochelle</bold>: supervision, writing-review and editing; <bold>Morgan</bold>: conceptualization, funding acquisition, resources, supervision, writing-review and editing</p></fn><corresp id="CR1"><underline>Corresponding author</underline>: Nicole McCann, <email>ncmccann@bu.edu</email>, 715 Albany St, Boston, MA, 02118, 413-687-4340</corresp><fn fn-type="COI-statement" id="FN2"><p id="P33"><underline>Declarations of Interest</underline>: None</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2023</year></pub-date><volume>159</volume><issue-id pub-id-type="pmc-issue-id">458109</issue-id><fpage>209281</fpage><lpage>209281</lpage><pub-history><event event-type="nihms-submitted"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-01 00:25:45.780"><day>01</day><month>04</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1954143.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction</title><p id="P3">Buprenorphine and naltrexone are effective medications for opioid use disorder (MOUD). Naltrexone requires complete detoxification from opioids before initiation while buprenorphine does not, which leads to a differential clinical induction challenge. Few studies have evaluated economic costs associated with MOUD initiation.</p></sec><sec id="S2"><title>Methods</title><p id="P4">We conducted a retrospective cohort analysis using the 2014&#8211;2019 Merative MarketScan database. We included individuals diagnosed with opioid use, abuse, or dependence from 2014 to 2019 who initiated one of three MOUD types: 1) buprenorphine, 2) extended-release naltrexone, or 3) oral naltrexone. We calculated total and monthly out-of-pocket spending, for overall and MOUD-specific claims, for the three months prior through three months after MOUD initiation. We also calculated utilization of detoxification, inpatient, and outpatient services monthly over this period.</p></sec><sec id="S3"><title>Results</title><p id="P5">Our cohort included 27,133 individuals; 19,536, 1,886, and 5,711 initiated buprenorphine, extended-release naltrexone, and oral naltrexone, respectively. Individuals who initiated naltrexone had the highest out-of-pocket spending over the study period. MOUD-specific spending did not contribute substantially to total out-of-pocket spending. Difference in overall spending by MOUD type was driven by a subset of individuals who initiated naltrexone and had very high out-of-pocket spending in the month prior to MOUD initiation. In this month, mean monthly out-of-pocket spending for high-spenders (above 90th percentile within MOUD type category) was $5,734 (95% confidence interval [CI]: $5,181&#8211;$6,286) and $4,622 (95% CI: $4,161&#8211;$5,082) for those who initiated oral and extended-release naltrexone, respectively, compared with $1,852 (95% CI: $1,754&#8211;$1,950) for those who initiated buprenorphine. In the month prior to MOUD initiation, those who initiated naltrexone also had higher detoxification, inpatient, and outpatient episode/visit frequency. In the month prior to initiation, 28.8% (95% CI: 27.7%&#8211;30.0%) and 25.5% (95% CI: 23.6%&#8211;27.5%) of individuals who initiated oral and extended-release naltrexone had detoxification episodes, compared with 9.7% (95% CI: 9.3%&#8211;10.1%) of those who initiated buprenorphine.</p></sec><sec id="S4"><title>Conclusion</title><p id="P6">Findings suggest that individuals who initiated naltrexone utilized more intensive health services, including detoxification, in the period prior to MOUD initiation, resulting in significantly higher out-of-pocket spending. Out-of-pocket spending is a patient-centered outcome reflecting potential patient burden. Our results should be considered as part of the shared decision-making process between patients and providers when choosing treatment for OUD.</p></sec></abstract><kwd-group><kwd>opioid-related disorders [MeSH]</kwd><kwd>expenditures</kwd><kwd>out-of-pocket [MeSH] patient centered care [MeSH]</kwd><kwd>medications for opioid use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>